Management of Gallbladder Carcinoma

Preoperative Workup and Staging

High-quality cross-sectional imaging (CT/MRI) is used to evaluate tumor penetration through the gallbladder wall, direct organ invasion, vascular involvement, and nodal/distant metastases, as recommended by the National Comprehensive Cancer Network 1
Chest imaging is used to exclude pulmonary metastases, as recommended by the National Comprehensive Cancer Network 1
Staging laparoscopy is recommended before laparotomy for potentially curative resection to identify occult peritoneal or hepatic metastases and avoid unnecessary laparotomy, as recommended by the National Comprehensive Cancer Network 1
PET scanning is increasingly useful for detecting distant metastatic disease in otherwise potentially resectable cases, as recommended by the National Comprehensive Cancer Network 1
MRCP is preferred over ERCP or PTC unless therapeutic intervention is planned, as recommended by the National Comprehensive Cancer Network 1
Preoperative biliary drainage should be considered selectively, though controversy exists regarding routine use, as noted by the National Comprehensive Cancer Network 2
CA 19-9 and CEA may be elevated but are not specific for gallbladder cancer, as reported by the National Comprehensive Cancer Network 1

Cholecystectomy with en bloc hepatic resection and lymphadenectomy is the standard operation for resectable disease, as recommended by the National Comprehensive Cancer Network 1
Hepatic resection should include segments IVb and V (wedge resection minimum) to achieve R0 margins, as recommended by the National Comprehensive Cancer Network 1
Major hepatectomy should only be performed when necessary to remove disease, as it increases complications without independent survival benefit, as noted by the National Comprehensive Cancer Network 1
Lymphadenectomy must include porta hepatis, gastrohepatic ligament, and retroduodenal regions, as recommended by the National Comprehensive Cancer Network 1
Nodal disease beyond these regions (celiac, retropancreatic) indicates unresectable disease, as reported by the National Comprehensive Cancer Network 1
Bile duct resection is not routinely required but should be performed when necessary to achieve negative margins, as recommended by the National Comprehensive Cancer Network 1

Gemcitabine plus cisplatin is the standard first-line regimen for advanced disease, as recommended by the National Comprehensive Cancer Network, although this specific citation is from Praxis Medical Insights 3
Gemcitabine plus oxaliplatin is an alternative if cisplatin is contraindicated, as noted by Praxis Medical Insights 3
Biliary stenting via ERCP is used for symptomatic obstruction, as recommended by Praxis Medical Insights 3
Metal stents are preferred over plastic stents if life expectancy exceeds 6 months, as noted by Praxis Medical Insights 3
Surgical bypass has not been demonstrated superior to stenting, as reported by Praxis Medical Insights 3
Fluoropyrimidine-based chemotherapy is used after progression, as recommended by Praxis Medical Insights 3
Clinical trial enrollment is encouraged, as recommended by the National Comprehensive Cancer Network 4
Best supportive care is an option, as noted by the National Comprehensive Cancer Network 4

Observation alone is acceptable after R0 resection with negative nodes, as recommended by the National Comprehensive Cancer Network 2
Adjuvant fluoropyrimidine chemoradiation or fluoropyrimidine/gemcitabine chemotherapy may be considered, as noted by the National Comprehensive Cancer Network 2
Clinical trial enrollment is encouraged given limited data, as recommended by the National Comprehensive Cancer Network 2
After R1/R2 resection or positive nodes, multidisciplinary review is required with options including additional resection, fluoropyrimidine chemoradiation, and fluoropyrimidine- or gemcitabine-based chemotherapy, as recommended by the National Comprehensive Cancer Network 4

No data support aggressive surveillance protocols, as noted by the National Comprehensive Cancer Network 2
Consider imaging every 6 months for 2 years, as recommended by the National Comprehensive Cancer Network 2
Re-evaluate according to initial workup if disease progression occurs, as noted by the National Comprehensive Cancer Network 2

Attempting radical resection in the presence of peritoneal spread represents stage IVB disease requiring systemic therapy, not surgery, as noted by Praxis Medical Insights 3
Performing major hepatectomy or bile duct excision unnecessarily when not required for R0 resection, as reported by the National Comprehensive Cancer Network 1
Delaying palliative chemotherapy while pursuing multiple surgical opinions in metastatic disease, as noted by Praxis Medical Insights 3
Neglecting biliary drainage in symptomatic obstruction, as reported by Praxis Medical Insights 3

Five-year survival rates by stage are 60% (stage 0), 39% (stage I), 15% (stage II), 5% (stage III), 1% (stage IV), as reported by the National Comprehensive Cancer Network 1
Median survival for stage Ia-III is 12 months; stage IV is 5.8 months, as noted by the National Comprehensive Cancer Network 1
R0 resection status is the most important predictor of survival, as reported by BioScience Trends 5